A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)

2024-518780-36-00 Protocol CLN-978-SL-101 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 10 Dec 2025 · Status Ongoing, recruiting · 6 EU/EEA countries · 11 sites · Protocol CLN-978-SL-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 72
Countries 6
Sites 11

Systemic Lupus Erythematosus

Key facts

Sponsor
Cullinan Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
10 Dec 2025 → ongoing
Decision date (initial)
2025-11-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518780-36-00
ClinicalTrials.gov
NCT06613360

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Systemic Lupus Erythematosus

VersionLevelCodeTermSystem organ class
21.1 PT 10042945 Systemic lupus erythematosus 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cullinan Therapeutics Inc.

Sponsor organisation
Cullinan Therapeutics Inc.
Address
1 Main Street Suite 1350
City
Cambridge
Postcode
02142-1531
Country
United States

Scientific contact point

Organisation
Cullinan Therapeutics Inc.
Contact name
Study Responsible Physician

Public contact point

Organisation
Cullinan Therapeutics Inc.
Contact name
Study Responsible Physician

Locations

6 EU/EEA countries · 11 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ongoing, recruiting 8 1
France Authorised, recruiting 4 3
Germany Authorised, recruitment pending 10 1
Poland Authorised, recruitment pending 6 3
Romania Ongoing, recruiting 12 2
Spain Authorised, recruitment pending 4 1
Rest of world
United States, Moldova, Republic of, Georgia, Australia
28

Investigational sites

Bulgaria

1 site · Ongoing, recruiting
Multispecialty hospital for active treatment Sveta Sofia EOOD
Internal Diseases, Bulevard Bilgariya 104, 1404, Sofiya

France

3 sites · Authorised, recruiting
Centre Hospitalier Universitaire De Toulouse
Service Medecine Interne et immunologie clinique, 1 Avenue Du Professeur Jean Poulhes, Tsa 50032, Toulouse Cedex 9
Centre Hospitalier Universitaire De Nantes
Service Medecine Interne, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Universitaire De Saint Etienne
Service Medecine Interne, St Priest En Jarez, 25 Boulevard Pasteur, St Etienne Cedex 2

Germany

1 site · Authorised, recruitment pending
Universitaetsklinikum Heidelberg AöR
Medizinische Klinik V/ Sektion Rheumatologie, Im Neuenheimer Feld 410, Neuenheim, Heidelberg

Poland

3 sites · Authorised, recruitment pending
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Nie dotyczy, Ul. Spartanska 1, 02-637, Warsaw
Malopolskie Centrum Kliniczne
Nie dotyczy, Ul. Balicka 12a/5b, 30-149, Cracow
Medicover Integrated Clinical Services Sp. z o.o.
MICS Centrum Medyczne Warszawa, Chłodna, Ul. Chlodna 52, 00-872, Warsaw

Romania

2 sites · Ongoing, recruiting
Arensia Clinics S.R.L.
3rd Floor, Wards 1, 2, 3, 4, 5, 6 and 7, Intrarea Tudor Stefan 38-40, 011658, Bucharest
Spitalul Clinic Judetean De Urgenta Cluj
Ophthalmology Building, Strada Clinicilor 3-5, 400006, Cluj-Napoca

Spain

1 site · Authorised, recruitment pending
Hospital Quironsalud Infanta Luisa
Rheumatology, Calle De San Jacinto 87, 41010, Sevilla

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-12-10 2025-12-17
France 2026-05-06
Romania 2026-03-19 2026-03-26

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-15 Bulgaria Acceptable
2025-11-24
2025-11-25
2 SUBSEQUENT ADDITION OF MSC APP-2 2025-12-05 2026-03-16
3 SUBSEQUENT ADDITION OF MSC APP-3 2026-01-19 Acceptable
2025-11-24
2026-04-10
4 SUBSEQUENT ADDITION OF MSC APP-4 2026-01-19 Acceptable
2025-11-24
2026-04-08
5 SUBSEQUENT ADDITION OF MSC APP-5 2026-01-28 Acceptable
2025-11-24
2026-04-01
6 SUBSEQUENT ADDITION OF MSC APP-6 2026-02-02 Acceptable
2025-11-24
2026-04-29
7 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-06 Bulgaria Acceptable
2025-11-24
2026-05-06
8 NON SUBSTANTIAL MODIFICATION NSM-2 2026-05-06 Bulgaria Acceptable
2025-11-24
2026-05-06
9 NON SUBSTANTIAL MODIFICATION NSM-3 2026-05-08 Acceptable
2025-11-24
2026-05-08
10 NON SUBSTANTIAL MODIFICATION NSM-4 2026-05-20 Acceptable
2025-11-24
2026-05-20